Arginase as a potential target in the treatment of cardiovascular disease: Reversal of arginine steal?

Cardiovascular Research

Volumn 98, Issue 3, 2013, Pages 334-343

  Pernow, John ^a   Jung, Christian ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Arginase; Atherosclerosis; Diabetes mellitus; Hypertension; Ischaemia; Nitric oxide; Reactive oxygen species

Indexed keywords

ARGINASE; ARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE;

AGING; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME LOCALIZATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW;

ARGINASE; ATHEROSCLEROSIS; DIABETES MELLITUS; HYPERTENSION; ISCHAEMIA; NITRIC OXIDE; REACTIVE OXYGEN SPECIES;

ANIMALS; ARGINASE; ARGININE; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS;

EID: 84877951082     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt036     Document Type: Review

References (106)

1. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J et al. Endo-thelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:233-246.
2. Munzel T, Heitzer T, Harrison DG. The physiology and pathophysiology of the nitric oxide/superoxide system. Herz 1997;22:158-172.
3. Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 2007;34:906-911.
4. Ash DE, Cox JD, Christianson DW. Arginase: a binuclear manganese metalloenzyme. Met Ions Biol Syst 2000;37:407-428.
5. Morris SM Jr. Arginine metabolism in vascular biology and disease. Vasc Med 2005; 10(Suppl 1):S83-S87.
6. Chicoine LG, Paffett ML, Young TL, Nelin LD. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol 2004;287:L60-L88.
7. Nelin LD, Wang X, Zhao Q, Chicoine LG, Young TL, Hatch DM et al. MKP-1 switches arginine metabolism from nitric oxide synthase to arginase following endo-toxin challenge. Am J Physiol Cell Physiol 2007;293:C632-C640.
8. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V et al. Dys-regulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. J Am Med Assoc 2005;294:81-90.
9. Munder M. Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol 2009;158:638-651.
10. Ryoo S, Lemmon CA, Soucy KG, Gupta G, White AR, Nyhan D et al. Oxidized lowdensity lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res 2006;99:951-960.
11. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 2008;102:95-102.
12. Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, Mazzolai L et al. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 2004; 110:3708-3714.
13. Prieto CP, Krause BJ, Quezada C, San Martin R, Sobrevia L, Casanello P. Hypoxia-reduced nitric oxide synthase activity is partially explained by higher ', arginase-2 activity and cellular redistribution in human umbilical vein endothelium. Placenta 2011;32:932-940.
14. Chen B, Calvert AE, Cui H, Nelin LD. Hypoxia promotes human pulmonary artery smooth muscle cell proliferation through induction of arginase. Am J Physiol Lung Cell Mol Physiol 2009;297:L1151-L1159.
15. Toque HA, Romero MJ, Tostes RC, Shatanawi A, Chandra S, Carneiro ZN et al. p38 Mitogen-activated protein kinase (MAPK) increases arginase activity and contributes to endothelial dysfunction in corpora cavernosa from angiotensin-II-treated mice. J Sex Med 2010;7:3857-3867.
16. 2 impairs endothelium-dependent nitric oxide-mediated dilation of coronary arterioles. Arterioscler Thromb Vasc Biol 2006;26:2035-2042.
17. Sankaralingam S, Xu H, Davidge ST. Arginase contributes to endothelial cell oxidative stress in response to plasma from women with preeclampsia. Cardiovasc Res 2010;85:194-203.
18. Chandra S, Romero M, Shatanawi A, Alkilany A, Caldwell R. Oxidative species increase arginase activity in endothelial cells through the RhoA/Rho kinase pathway. Br J Pharmacol 2012;165:506-519.
19. Zhang W, Baban B, Rojas M, Tofigh S, Virmani SK, Patel C et al. Arginase activity mediates retinal inflammation in endotoxin-induced uveitis. Am J Pathol 2009;175: 891-902.
20. Horowitz S, Binion DG, Nelson VM, Kanaa Y, Javadi P, Lazarova Z et al. Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2007;292:G1323-G1336.
21. Yao L, Chandra S, Toque HA, Bhatta A, Rojas M, Caldwell RB et al. Prevention of diabetes-induced arginase activation and vascular dysfunction by Rho kinase (ROCK) knockout. Cardiovasc Res 2013;97:509-519.
22. Chang CI, Zoghi B, Liao JC, Kuo L. The involvement of tyrosine kinases, cyclic AMP/protein kinase A, and p38 mitogen-activated protein kinase in IL-13-mediated arginase I induction in macrophages: its implications in IL-13-inhibited nitric oxide production. J Immunol 2000;165:2134-2141.
23. Santhanam L, Lim HK, Miriel V, Brown T, Patel M, Balanson S et al. Inducible NO synthase dependent S-nitrosylation and activation of arginase1 contribute to age-related endothelial dysfunction. Circ Res 2007;101:692-702.
24. Ryoo S, Bhunia A, Chang F, Shoukas A, Berkowitz DE, Romer LH. OxLDLdependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling. Atherosclerosis 2011;214:279-287.
25. Michell DL, Andrews KL, Chin-Dusting JP. Endothelial dysfunction in hypertension: the role of arginase. Front Biosci (Schol Ed) 2011;3:946-960.
26. Santhanam L, Christianson DW, Nyhan D, Berkowitz DE. Arginase and vascular aging.J Appl Physiol 2008;105:1632-1642.
27. Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J 2012;33:829-837.
28. Kim JH, Bugaj LJ, Oh YJ, Bivalacqua TJ, Ryoo S, Soucy KG et al. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J Appl Physiol 2009;107:1249-1257.
29. Ross R. Atherosclerosis-an inflammatory disease. N EnglJ Med 1999;340:115-126.
30. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23:168-175.
31. Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, Sikka G et al. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 2008;102:923-932.
32. Erdely A, Kepka-Lenhart D, Salmen-Muniz R, Chapman R, Hulderman T, Kashon M et al. Arginase activities and global arginine bioavailability in wild-type and ApoE-deficient mice: responses to high fat and high cholesterol diets. PLoS One 2010;5: e15253.
33. Hayashi T, Esaki T, Sumi D, Mukherjee T, Iguchi A, Chaudhuri G. Modulating role of estradiol on arginase II expression in hyperlipidemic rabbits as an atheroprotective mechanism. Proc Natl Acad Sci USA 2006;103:10485-10490.
34. Laufs U, Liao JK Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 2000;10:143-148.
35. Wang W, Hein TW, Zhang C, Zawieja DC, Liao JC, Kuo L Oxidized low-density lipoprotein inhibits nitric oxide-mediated coronary arteriolar dilation by up-regulating endothelial arginase I. Microcirculation 2011;18:36-45.
36. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995;92:8264-8268.
37. Corraliza IM, Soler G, Eichmann K, Modolell M. Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages. Biochem Biophys Res Commun 1995;206:667-673.
38. Gallardo-Soler A, Gomez-Nieto C, Campo ML, Marathe C, Tontonoz P, Castrillo A et al. Arginase I induction by modified lipoproteins in macrophages: a peroxisome proliferator-activated receptor-gamma/delta-mediated effect that links lipid metabolism and immunity. Mol Endocrinol 2008;22:1394-1402.
39. Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M et al. Macrophage plasticity in experimental atherosclerosis. PLoS One 2010;5:e8852.
40. Yang Z, Ming XF. Endothelial arginase: a new target in atherosclerosis. Curr Hypertens Rep 2006;8:54-59.
41. Wei LH, Wu G, Morris SM Jr., Ignarro LJ. Elevated arginase I expression in rat aortic smooth muscle cells increases cell proliferation. Proc Natl Acad Sci USA 2001;98: 9260-9264.
42. Peyton KJ, Ensenat D, Azam MA, Keswani AN, Kannan S, Liu XM et al. Arginase promotes neointima formation in rat injured carotid arteries. Arterioscler Thromb Vasc Biol 2009;29:488-494.
43. Wang XP, Chen YG, Qin WD, Zhang W, Wei SJ, Wang J et al. Arginase I attenuates inflammatory cytokine secretion induced by lipopolysaccharide in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2011;31:1853-1860.
44. Teupser D, Burkhardt R, Wilfert W, Haffner I, Nebendahl K, Thiery J. Identification of macrophage arginase I as a new candidate gene of atherosclerosis resistance. Arterioscler Thromb Vasc Biol 2006;26:365-371.
45. Getz GS, Reardon CA. Arginine/arginase NO NO NO. Arterioscler Thromb Vasc Biol 2006;26:237-239.
46. Porembska Z, Kedra M. Occurrence of arginase in human blood serum in patients with myocardial infarction. Bull Acad Pol Sci Biol 1970;18:137-140.
47. Porembska Z, Kedra M. Early diagnosis of myocardial infarction by arginase activity determination. Clin Chim Acta 1975;60:355-361.
48. Smirnov VN, Asafov GB, Cherpachenko NM, Chernousova GB, Mozzhechkov VT, Krivov VI et al. Ammonia neutralization and urea synthesis in cardiac muscle. Circ Res 1974;35(Suppl 3):58-73.
49. Hein TW, Zhang C, Wang W, Chang CI, Thengchaisri N, Kuo L. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J 2003;17:2328-2330.
50. Jung C, Gonon AT, Sjoquist PO, Lundberg JO, Pernow J. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res 2010;85:147-154.
51. Gonon AT, Jung C, Katz A, Westerblad H, Shemyakin A, Sjoquist PO et al. Local argi-nase inhibition during early reperfusion mediates cardioprotection via increased nitric oxide production. PLoS One 2012;7:e42038.
52. Gao X, Xu X, Belmadani S, Park Y, Tang Z, Feldman AM et al. TNF-alpha contributes to endothelial dysfunction by upregulating arginase in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 2007;27:1269-1275.
53. Zhao YJ, Zhang WH, Xu CQ, Li HZ, Wang LN, Li H et al. Involvement of the or-nithine decarboxylase/polyamine system in precondition-induced cardioprotection through an interaction with PKC in rat hearts. Mol Cell Biochem 2009;332:135-144.
54. Zhao YJ, Xu CQ, Zhang WH, Zhang L, Bian SL, Huang Q et al. Role of polyamines in myocardial ischemia/reperfusion injury and their interactions with nitric oxide. Eur J Pharmacol 2007;562:236-246.
55. Clarkson AN, Liu H, Pearson L, Kapoor M, Harrison JC, Sammut IA et al. Neuropro-tective effects of spermine following hypoxic-ischemic-induced brain damage: a mechanistic study. FASEB J 2004;18:1114-1116.
56. Tang Y, Xu H, Du X, Lit L, Walker W, Lu A et al. Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J Cereb Blood Flow Metab 2006;26:1089-1102.
57. Barr TL, Conley Y, Ding J, Dillman A, Warach S, Singleton A et al. Genomic biomar-kers and cellular pathways of ischemic stroke by RNA gene expression profiling. Neurology 2010;75:1009-1014.
58. Aladag MA, Turkoz Y, Parlakpinar H, Ozen H, Egri M, Unal SC. Melatonin ameliorates cerebral vasospasm after experimental subarachnoidal haemorrhage correcting imbalance of nitric oxide levels in rats. Neurochem Res 2009;34:1935-1944.
59. Bitner BR, Brink DC, Mathew LC, Pautler RG, Robertson CS. Impact of arginase II on CBF in experimental cortical impact injury in mice using MRI. J Cereb Blood Flow Metab 2010;30:1105-1109.
60. Gall MA, Rossing P, Skott P, Damsbo P, Vaag A, Bech K et al. Prevalence of microand macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991;34: 655-661.
61. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108:1527-1532.
62. Toque HA, Tostes RC, Yao L, Xu Z, Webb RC, Caldwell RB et al. Arginase II deletion increases corpora cavernosa relaxation in diabetic mice. J Sex Med 2011;8: 722-733.
63. Sun C, Sun L, Ma H, Peng J, Zhen Y, Duan K et al. The phenotype and functional alterations of macrophages in mice with hyperglycemia for long term. J Cell Physiol 2012;227:1670-1679.
64. Grönros J, Jung C, Lundberg JO, Cerrato R, Ostenson CG, Pernow J. Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats. Am J Physiol 2011;300:H1174-H1181.
65. Kashyap SR, Lara A, Zhang R, Park YM, DeFronzo RA. Insulin reduces plasma argi-nase activity in type 2 diabetic patients. Diabetes Care 2008;31:134-139.
66. Ogino K, Takahashi N, Takigawa T, Obase Y, Wang DH. Association of serum argi-nase I with oxidative stress in a healthy population. Free Radic Res 2011;45:147-155.
67. Romero MJ, Iddings JA, Platt DH, Ali MI, Cederbaum SD, Stepp DW et al. Diabetes-induced vascular dysfunction involves arginase I. Am J Physiol Heart Circ Physiol 2012;302:H159-H166.
68. Elms SC, Toque HA, Rojas M, Xu Z, Caldwell RW, Caldwell RB. The role of arginase I in diabetes-induced retinal vascular dysfunction in mouse and rat models of diabetes. Diabetologia 2013;56:654-662.
69. Beleznai T, Feher A, Spielvogel D, Lansman SL, Bagi Z. Arginase 1 contributes to diminished coronary arteriolar dilation in patients with diabetes. Am J Physiol 2011; 300:H777-H783.
70. Shemyakin A, Kovamees O, Rafnsson A, Bohm F, Svenarud P, Settergren M et al. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation 2012;126:2943-2950.
71. Zairis MN, Patsourakos NG, Tsiaousis GZ, Theodossis Georgilas A, Melidonis A, Makrygiannis SS et al. Plasma asymmetric dimethylarginine and mortality in patients with acute decompensation of chronic heart failure. Heart 2012;98:860-864.
72. Maxwell AJ. Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases. Nitric Oxide 2002;6:101-124.
73. Heusch P, Aker S, Boengler K, Deindl E, van de Sand A, Klein K et al. Increased in-ducible nitric oxide synthase and arginase II expression in heart failure: no net nitrite/nitrate production and protein S-nitrosylation. Am J Physiol Heart Circ Physiol 2010; 299:H446-H453.
74. Jung AS, Kubo H, Wilson R, Houser SR, Margulies KB. Modulation of contractility by myocyte-derived arginase in normal and hypertrophied feline myocardium. Am J Physiol Heart Circ Physiol 2006;290:H1756-H1762.
75. Post H, Pieske B. Arginase: a modulator of myocardial function. Am J Physiol Heart Circ Physiol 2006;290:H1747-H1748.
76. Richir MC, van Lambalgen AA, Teerlink T, Wisselink W, Bloemena E, Prins HA et al. Low arginine/asymmetric dimethylarginine ratio deteriorates systemic hemodynam-ics and organ blood flow in a rat model. Crit Care Med 2009;37:2010-2017.
77. Steppan J, Ryoo S, Schuleri KH, Gregg C, Hasan RK, White AR et al. Arginase modulates myocardial contractility by a nitric oxide synthase 1-dependent mechanism. Proc Natl Acad Sci USA 2006;103:4759-4764.
78. Quitter F, Figulla HR, Ferrari M, Pernow J, Jung C. Increased arginase levels in heart failure represent a therapeutic target to rescue microvascular perfusion. Clin Hemor-heol Microcirc. Advance Access published October 17, 2012, doi: 10.3233/CH-2012-1617.
79. Luscher TF. The endothelium in hypertension: bystander, target or mediator? J Hypertens 1994;12:S105-S116.
80. Demougeot C, Prigent-Tessier A, Bagnost T, Andre C, Guillaume Y, Bouhaddi M et al. Time course of vascular arginase expression and activity in spontaneously hypertensive rats. Life Sci 2007;80:1128-1134.
81. Rodriguez S, Richert L, Berthelot A. Increased arginase activity in aorta of mineralocorticoid-salt hypertensive rats. Clin Exp Hypertens 2000;22:75-85.
82. Johnson FK, Johnson RA, Peyton KJ, Durante W. Arginase inhibition restores arteri-olar endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2005;288:R1057-R1062.
83. Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, McDonald MM et al. Upre-gulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 2004;44:935-943.
84. Bagnost T, Berthelot A, Alvergnas M, Miguet-Alfonsi C, Andre C, Guillaume Y et al. Misregulation of the arginase pathway in tissues of spontaneously hypertensive rats. Hypertens Res 2009;32:1130-1135.
85. Bagnost T, Berthelot A, Bouhaddi M, Laurant P, Andre C, Guillaume Y et al. Treatment with the arginase inhibitor N(omega)-hydroxy-nor-L-arginine improves vascular function and lowers blood pressure in adult spontaneously hypertensive rat. J Hypertens 2008;26:1110-1118.
86. Huynh NN, Andrews KL, Head GA, Khong SM, Mayorov DN, Murphy AJ et al. Argi-nase II knockout mouse displays a hypertensive phenotype despite a decreased vaso-constrictory profile. Hypertension 2009;54:294-301.
87. Waki H, Murphy D, Yao ST, Kasparov S, Paton JF. Endothelial NO synthase activity in nucleus tractus solitarii contributes to hypertension in spontaneously hypertensive rats. Hypertension 2006;48:644-650.
88. Holowatz LA, Kenney WL. Up-regulation of arginase activity contributes to attenuated reflex cutaneous vasodilatation in hypertensive humans. J Physiol 2007;581: 863-872.
89. Kosenko E, Tikhonova L, Suslikov A, Kaminsky Y. Impacts of lisinopril and lisinopril plus simvastatin on erythrocyte and plasma arginase, nitrite, and nitrate in hypertensive patients. J Clin Pharmacol 2012;52:102-109.
90. Zuckerbraun BS, George P, Gladwin MT. Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling. Cardiovasc Res 2011;89:542-552.
91. Langle F, Roth E, Steininger R, Winkler S, Muhlbacher F. Arginase release following liver reperfusion. Evidence of hemodynamic action of arginase infusions. Transplantation 1995;59:1542-1549.
92. Morris CR, Gladwin MT, Kato GJ. Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med 2008;8: 620-632.
93. Watts JA, Marchick MR, Gellar MA, Kline JA. Up-regulation of arginase II contributes to pulmonary vascular endothelial cell dysfunction during experimental pulmonary embolism. Pulm Pharmacol Ther 2011;24:407-413.
94. Watts JA, Gellar MA, Fulkerson MB, Das SK, Kline JA. Arginase depletes plasma l-arginine and decreases pulmonary vascular reserve during experimental pulmonary embolism. Pulm Pharmacol Ther 2012;25:48-54.
95. Krotova K, Patel JM, Block ER, Zharikov S. Hypoxic upregulation of arginase II in human lung endothelial cells. Am J Physiol Cell Physiol 2010;299:C1541-C1548.
96. Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, Goggans T et al. Increased argi-nase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 2004;18:1746-1748.
97. Beyer J, Kolditz M, Ewert R, Rubens C, Opitz C, Schellong S et al. L-Arginine plasma levels and severity of idiopathic pulmonary arterial hypertension. Vasa 2008;37: 61-67.
98. Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003;108:2000-2006.
99. Badaut J, Copin JC, Fukuda AM, Gasche Y, Schaller K, da Silva RF. Increase of argi-nase activity in old apolipoprotein E deficient mice under Western diet associated with changes in neurovascular unit. J Neuroinflammation 2012;9:132.
100. White AR, Ryoo S, Li D, Champion HC, Steppan J, Wang D et al. Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension 2006; 47:245-251.
101. Holowatz LA, Thompson CS, Kenney WL. L-Arginine supplementation or arginase inhibition augments reflex cutaneous vasodilatation in aged human skin. J Physiol 2006;574:573-581.
102. Schade D, Kotthaus J, Clement B. Modulating the NO generating system from a medicinal chemistry perspective: current trends and therapeutic options in cardiovascular disease. Pharmacol Therap 2010;126:279-300.
103. Bagnost T, Ma L, da Silva RF, Rezakhaniha R, Houdayer C, Stergiopulos N et al. Cardiovascular effects of arginase inhibition in spontaneously hypertensive rats with fully developed hypertension. Cardiovasc Res 2010;87:569-577.
104. Dunn J, Gutbrod S, Webb A, Pak A, Jandu SK, Bhunia A et al. S-nitrosation of argi-nase 1 requires direct interaction with inducible nitric oxide synthase. Mol Cell Biochem 2011;355:83-89.
105. Thacher TN, Gambillara V, Riche F, Silacci P, Stergiopulos N, da Silva RF. Regulation of arginase pathway in response to wall shear stress. Atherosclerosis 2010;210:63-70.
106. Munder M, Mollinedo F, Calafat J, Canchado J, Gil-Lamaignere C, Fuentes JM et al. Arginase I is constitutively expressed in human granulocytes and participates in fun-gicidal activity. Blood 2005;105:2549-2556.